A potential immunotherapeutic and prognostic biomarker for multiple tumors including glioma: SHOX2

Hereditas

Research

Hui Chen¹  Xiaocong Wu¹  Zongjun Peng¹  Chao You² 

[1] Department of Neurosurgery, Sichuan Friendship Hospital, 96 Shangshahepu Street, Jinjiang District, 610066, Chengdu, Sichuan, China;Department of Neurosurgery, West China Hospital, Sichuan University, 37 Guoxue Lane, Wuhou District, 610041, Chengdu, Sichuan, China;

关键词: SHOX2;    Pan-cancer;    Prognosis;    Immune;    Glioma;   

DOI  :  10.1186/s41065-023-00279-8

 received in 2023-02-13, accepted in 2023-04-06,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundShort stature homeobox 2 (SHOX2) is significant gene in the development and progression of multiple types of tumors. Nonetheless, the biological role of SHOX2 within pan-cancer datasets has not been investigated. Thus, comprehensive bioinformatics analyses of pan-cancer datasets were conducted to explore how SHOX2 regulates tumorigenesis.MethodsA variety of tumor datasets and online analytical tools, including SangerBox, TIMER2, LinkedOmic, GEPIA2 and cBioPortal, were applied to explore SHOX2 expression in various tumors. To ascertain the connections between SHOX2 expression and genetic alterations, SHOX2-related genes and tumor immunity, the pan-cancer datasets were examined. In vitro assays were applied to verify the biological functions of SHOX2 in glioma cells via CCK-8, wound healing, Transwell and colony formation assays.ResultsAnalyses found that SHOX2 was overexpressed in multiple cancer types. SHOX2 expression level was significantly correlated with isocitrate dehydrogenase (IDH), 1p/19q, O6-methylguanine DNA methyltransferase (MGMT) status and new types of glioma patients. High mRNA expression levels of SHOX2 were associated with a poor prognosis in multiple tumor patients. KEGG enrichment analysis showed that SHOX2-related genes were associated with cell cycle and DNA damage repair. Genetic alterations of SHOX2 were identified in multiple types of cancers, including duplications and deep mutations. Immune analysis showed that SHOX2 was closely correlated with the tumor mutation burden (TMB), microsatellite instability (MSI), neoantigen and neoantigens and immune checkpoint (ICP) in a variety of tumors and could influence the immunotherapy sensitivity of cancers. CCK-8, wound healing, Transwell and colony formation experiments showed that SHOX2 knockdown inhibited glioma cell proliferation, migration, invasion and colony formation abilities.ConclusionSHOX2 was overexpressed in multiple cancer types in TCGA cohort. SHOX2 knockdown inhibited glioma cell proliferation, migration and colony formation ability. Our study showed that SHOX2 may be an immunotherapeutic and promising prognostic biomarker in certain types of tumors.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

40517_2023_256_Article_IEq98.gif

40517_2023_256_Article_IEq79.gif

Fig. 3

Fig. 1

40517_2023_256_Article_IEq51.gif

Fig. 1

40517_2023_256_Article_IEq33.gif

40517_2023_258_Article_IEq130.gif

40517_2023_258_Article_IEq121.gif